share_log

HC Wainwright & Co. Maintains Buy on BioLine Rx, Raises Price Target to $21

HC Wainwright & Co. Maintains Buy on BioLine Rx, Raises Price Target to $21

HC Wainwright & Co.維持對BioLine Rx的買入,將目標價上調至21美元
Benzinga ·  2023/09/15 06:11

HC Wainwright & Co. analyst Joseph Pantginis maintains BioLine Rx (NASDAQ:BLRX) with a Buy and raises the price target from $19 to $21.

HC Wainwright&Co.分析師約瑟夫·潘特吉尼斯維持Bioline Rx(納斯達克代碼:BLRX)的買入,並將目標價從19美元上調至21美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論